ASCO GU 2018 Prostate Cancer - Results from #14

Viewing 15-34 of 88 articles

ASCO GU 2018: Influence of CHAARTED, STAMPEDE, and LATITUDE eligibility criteria on utilization of abiraterone and docetaxel

ASCO GU 2018: A Phase 2 Study of Olaparib and Durvalumab in mCRPC in an Unselected Population

ASCO GU 2018: Blood-brain barrier penetration of darolutamide compared with enzalutamide using whole body autoradiography

ASCO GU 2018: Best of Journals: Prostate - Surgery

ASCO GU 2018: Addition of docetaxel to first-line long-term hormone therapy in prostate cancer (STAMPEDE)

ASCO GU 2018: Ability of multiparametric MRI to predict prostate tumor heterogeneity on targeted biopsy

ASCO GU 2018: Best of Journals 2017: Prostate Cancer – Radiotherapy

ASCO GU 2018: Case-Based Debate: Abiraterone Versus Docetaxel

ASCO GU 2018: Metformin and statin together may delay prostate cancer metastasis

ASCO GU 2018: Proportion of Biochemically-recurrent Prostate Cancer Patients with Durable Undetectable PSA After Short-course Androgen Deprivation Therapy

ASCO GU 2018: First Interim Analysis Of REASSURE, An Observational Study To Assess The Safety Of Radium-223 In Men With Metastatic Castration-resistant Prostate Cancer

ASCO GU 2018: Abiraterone Acetate in Patients Aged 75 or More with mCRPC in Both Pre-chemotherapy or Post-chemotherapy Settings

ASCO GU 2018: Immunotherapy for Biochemically Recurrent Prostate Cancer

ASCO GU 2018: Cabozantinib for metastatic castration-resistant prostate cancer (mCRPC) following docetaxel: Combined analysis of two phase III trials.

ASCO GU 2018: Evaluation of prostate cancer risk in men with PSA 1.5

ASCO GU 2018: Impact of Genomic Risk Scores on Treatment Decisions Following Radical Prostatectomy in a Prospective Medicare Registry

ASCO GU 2018: Adjuvant Enzalutamide (ENZA) for Men with Non-metastatic High-risk Prostate Cancer (HRPCa) After Radical Prostatectomy (RP).

ASCO GU 2018: Lu-177-labeled PSMA-I&T Radioligand Therapy for mCRPC

ASCO GU 2018: Daily Versus Weekly Prostate Cancer image-guided Radiotherapy: A Phase 3, Multi-center, Randomized Trial

ASCO GU 2018: Comparison of Enzalutamide and Bicalutamide in Patients with Non-metastatic Castration-resistant Prostate Cancer - STRIVE Study

1
2
3
4
5